长城国瑞证券给予泓博医药增持评级
Pharma Resources (Shanghai) Pharma Resources (Shanghai) (SZ:301230) Sou Hu Cai Jing·2025-09-03 07:29

Group 1 - The core viewpoint of the report is that Hongbo Pharmaceutical (301230.SZ) is given an "Accumulate" rating due to its robust revenue growth and continuous improvement in profitability [1] - The drug discovery segment maintains steady growth, while the commercialization segment continues to expand rapidly [1] - There is a significant increase in new order amounts and the number of new customers, indicating effective market expansion [1] - The CADD/AIDD platform continues to empower the company, and the achievements in the DiOrion platform construction are notable [1]